Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. - Wikidata - awgldk - TriplyDB

Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours.

Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours.

http://www.wikidata.org/entity/Q43256128

about

Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines Cellular immunotherapy for pediatric solid tumors Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis Management of pediatric and adult patients with medulloblastoma.Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients.Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem Overview of cellular immunotherapy for patients with glioblastoma.Immunotherapy of brain cancers: the past, the present, and future directions.Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.Cellular-based immunotherapies for patients with glioblastoma multiforme.Trial watch: Dendritic cell-based interventions for cancer therapy Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.Characterization of distinct immunophenotypes across pediatric brain tumor types.Immune-checkpoint blockade and active immunotherapy for glioma.Ependymomas: development of immunotherapeutic strategies.Treatment of high-grade glioma in children and adolescents.Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.Immunotherapy for the treatment of glioblastoma.What to do when there is no standard of care: A brief review of treatment options for glioblastoma in children Glioblastoma multiforme: State of the art and future therapeutics.Brain Tumor Immunotherapy: What have We Learned so Far?Vaccination strategies for neuro-oncology.Dendritic cell vaccines: A review of recent developments and their potential pediatric application.Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.Improving vaccine efficacy against malignant glioma Dendritic cell therapy for oncology roundtable conference.Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.Immunotherapeutic implications of the immunophenotype of pediatric brain tumors.Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis.A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.Resection and Immunotherapy for Recurrent Grade III Glioma Transcriptional co-expression regulatory network analysis for Snail and Slug identifies IL1R1 , an inflammatory cytokine receptor, to be preferentially expressed in ST-EPN- RELA and PF-EPN-A molecular subgroups of intracranial ependymomas

P2860

Q26772715-ACB9D4BF-FEE9-479C-B146-7FE5B9920BAC Q27014912-9E36C767-7479-4080-B3FB-ED68AA00C9C5 Q27348437-43E254B1-A29C-467F-B5DB-217ECAA68FFE Q30847947-10D6C883-4056-4C9C-A6F0-286C6FCA3560 Q33600115-C243E12B-04BC-43BD-9721-2649F97A2465 Q33691858-B0BC5C42-AF05-4DC7-A3AD-0DD93D2C1FC6 Q33796170-1D8A7237-A817-4338-9BF5-68D1F01F967E Q34189694-2210575C-C167-4445-B7EF-0AEA7B9A7559 Q34701587-3848E093-3D48-43A3-AEC8-4C0747DEAC12 Q34948627-08EC158D-76F2-4169-94A7-E8F6CF209360 Q35821404-F01C7A1E-6A83-467B-B38D-3F35808077E8 Q36388529-77A27110-B160-4C44-9438-E36905C8F1B6 Q36710917-08F8C0F9-F684-4AFF-874B-821519CEA77A Q37308164-F7F609D5-72E7-4288-AE7D-B056AB5A8DC6 Q37420586-A797AF69-DFB5-4A29-B4A6-9103FC2F7997 Q37678294-611D8319-4A23-4A14-9BC4-90D330927EDC Q37904503-4F5ED29B-52B7-4CB0-8C95-A6E7026D75BB Q37970682-3BEC4F64-90D3-4646-BE45-3377FE5AA065 Q37980026-7A5B13F7-714A-4CF6-8CCE-D9B9B64CD516 Q38032269-C77A6218-9E88-4C72-BC06-DA575D58CFA3 Q38225874-CBD1A485-E134-43F1-98BB-E761A489B418 Q38542113-C3646E58-7222-438A-8619-46FCACF87457 Q38620079-CAE050C4-3693-4860-944A-D020B8A9CE06 Q38849396-37835768-BB30-47A0-AF22-68940666CF2A Q38912265-46F8AA14-12F4-471F-9552-DCCFEE188A1A Q38953024-885011D9-690A-4920-96B1-3B4A28222060 Q39794478-C2C19420-DB44-4688-936F-98B388808693 Q41391698-8DD0D6D2-DBCE-468F-BB8F-A4CBE6E29BBB Q41966297-6470B1F4-2EE1-48CD-8E25-EA0228EC3345 Q42431588-503DF79B-FDC8-484E-B5AB-2A1C16115947 Q45933704-3A8EE323-E739-4C18-A554-7CFEDC6E3075 Q46469386-28EF60CE-5C54-493C-98D9-7D61994E3ACF Q54980235-311C3799-0688-4A98-A6F5-88CA8588BF47 Q58691159-0C5B6194-9E34-4850-B5DA-0855CFB54B67 Q59135007-169386FE-3ABA-40CD-A97C-FB97ED47D564

P2860

Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours.

http://www.wikidata.org/entity/Q43256128

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Adjuvant dendritic cell-based ...... with malignant brain tumours.

@en

Adjuvant dendritic cell-based ...... with malignant brain tumours.

@nl

type

label

Adjuvant dendritic cell-based ...... with malignant brain tumours.

@en

Adjuvant dendritic cell-based ...... with malignant brain tumours.

@nl

prefLabel

Adjuvant dendritic cell-based ...... with malignant brain tumours.

@en

Adjuvant dendritic cell-based ...... with malignant brain tumours.

@nl

P1433

Q43256128-80D96F5B-6AE8-4B73-938E-6341120919C4

P1476

Q43256128-6209D199-034D-4707-8741-C43E613EA9B8

P2093

Q43256128-3F78057D-596A-41FA-B272-C1C141576F43

Q43256128-89EB8DF9-8A65-49C4-B6F7-609A21F9396B

Q43256128-8DC68BA8-6D1C-458C-AB8E-9D78E2F50901

Q43256128-97239EDA-51CA-4C76-9E8F-C529B56FF2D7

Q43256128-D69049B2-D831-4CCE-90E9-EEF528F5E27E

Q43256128-EA715366-399A-40D6-A988-6A4955EA49B8

P2860

Q43256128-10082B50-9C72-432B-A204-FC1ADE2CDCE5

Q43256128-6DAD7C5B-B3DF-47FA-B942-5EC49841C111

Q43256128-EFF34ABD-7C67-443F-963F-C3A12D96B994

P304

Q43256128-4C253CD6-BFEE-41A2-AD6F-33076F4B1914

P31

Q43256128-7FA24247-254F-422C-A530-41BB79889802

P356

Q43256128-1B051C40-D963-418A-B174-FEBB37785153

P433

Q43256128-A66CA437-9420-414B-887D-7B6BC9F1FE9D

P478

Q43256128-FB8BEBC3-059D-4191-8249-9D9169970193

P50

Q43256128-7ECF6DDA-D15A-456B-B0A1-E055ACDEB21A

Q43256128-9C3B20CF-E0C5-4612-A94A-D27DA12D915D

P577

Q43256128-88214461-0350-4229-80B8-4640978B1FCA

P5875

Q43256128-DEC8094F-EFE8-434F-9890-C44D572C5322

P698

Q43256128-A27A5C13-5B69-4183-BD30-FA9CAF855E8B

P356

P1433

Pediatric Blood & Cancer

P1476

Adjuvant dendritic cell-based ...... with malignant brain tumours.

@en

P2093

Christof M Kramm

http://www.w3.org/2001/XMLSchema#string

Frank Van Calenbergh

http://www.w3.org/2001/XMLSchema#string

Hilko Ardon

http://www.w3.org/2001/XMLSchema#string

Johannes E A Wolff

http://www.w3.org/2001/XMLSchema#string

Stefaan W Van Gool

http://www.w3.org/2001/XMLSchema#string

Stefan Rutkowski

http://www.w3.org/2001/XMLSchema#string

P2860

Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide.

Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report.

Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality.

P304

519-525

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.22319

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Steven De Vleeschouwer

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38031551

http://www.w3.org/2001/XMLSchema#string

P698

19852061

http://www.w3.org/2001/XMLSchema#string